Highlights
- Bemnifosbuvir (BEM) demonstrates potent, dose-dependent inhibition of Hepatitis E virus (HEV) replication in both in vitro human hepatocyte systems and in vivo animal models.
- Combination therapy using bemnifosbuvir and ribavirin yields an additive antiviral effect, potentially allowing for lower doses of ribavirin to mitigate its hematological side effects.
- Extended treatment with bemnifosbuvir does not trigger rapid viral resistance in HEV Genotype 3, suggesting a robust therapeutic durability.
- In vivo gerbil models confirm that bemnifosbuvir significantly reduces viral loads and associated hepatic inflammation, supporting its transition to clinical evaluation.
Background
Hepatitis E virus (HEV) remains a leading cause of acute viral hepatitis worldwide, with an estimated 20 million infections occurring annually. While frequently self-limiting in immunocompetent individuals, HEV presents a severe clinical challenge for immunocompromised populations, including solid-organ transplant recipients, patients with HIV, and those with hematological malignancies. In these patients, HEV can transition into a chronic state, leading to rapid progression of liver fibrosis and cirrhosis.
Currently, there are no FDA-approved medications specifically indicated for chronic HEV. Clinicians rely on off-label use of ribavirin (RBV) or pegylated interferon-alpha. However, RBV is frequently associated with dose-limiting anemia and is contraindicated in pregnancy due to teratogenicity. Furthermore, RBV treatment failure occurs in approximately 15–20% of cases, often due to the emergence of viral variants. Consequently, there is an urgent unmet clinical need for novel, safe, and effective direct-acting antivirals (DAAs) targeting HEV replication.
Key Content
Identification and Screening of Bemnifosbuvir
The discovery of bemnifosbuvir (BEM, also known as AT-527) as an anti-HEV candidate resulted from a high-throughput, image-based screening of a comprehensive nucleotide/nucleoside analogue library. Researchers utilized a full-length HEV fluorescence reporter virus, which allowed for real-time monitoring of viral replication dynamics within host cells. BEM, an orally bioavailable prodrug of a guanosine nucleotide analogue, was originally developed for the treatment of Hepatitis C (HCV) and SARS-CoV-2. Its mechanism involves the inhibition of the viral RNA-dependent RNA polymerase (RdRp), a highly conserved enzyme essential for the replication of positive-sense single-stranded RNA viruses.
In Vitro Efficacy and Safety Profile
Validation of the screening results was conducted using authentic human hepatocyte culture systems. BEM exhibited potent antiviral activity against HEV Genotype 3 (the predominant genotype in Western countries) with an effective concentration (EC50) in the low micromolar range. Importantly, the study observed minimal cytotoxicity at therapeutic concentrations, yielding a high selectivity index. This safety profile is consistent with previous Phase I and II clinical data where BEM was evaluated for other viral indications, suggesting a favorable therapeutic window for human application.
Combination Therapy and Resistance Dynamics
A critical finding in this research is the additive effect observed when BEM is combined with ribavirin. This synergy is clinically significant; by utilizing BEM, physicians might be able to reduce the standard dose of ribavirin, thereby decreasing the risk of severe hemolytic anemia while maintaining or enhancing virological suppression. Furthermore, the study addressed the major concern of antiviral resistance. Unlike many other DAAs that select for resistance mutations within weeks, HEV-3 remained susceptible to BEM inhibition over extended treatment periods. This suggests that BEM may possess a high genetic barrier to resistance, likely due to the essential nature of the RdRp residues targeted by the nucleotide analogue.
In Vivo Validation in Gerbil Models
To confirm the translational potential of BEM, researchers employed a gerbil infection model, which closely mimics the viral kinetics and hepatic pathology of human HEV infection. Oral administration of BEM resulted in a significant, dose-dependent reduction in fecal and serum HEV RNA levels. Pathological examination of liver tissues showed a marked decrease in inflammatory infiltrates and hepatocyte necrosis compared to untreated controls. These results provide strong evidence that BEM can reach therapeutic concentrations in liver tissue and effectively control viral-induced organ damage.
Expert Commentary
The identification of bemnifosbuvir as a potent anti-HEV agent marks a significant milestone in the field of hepatology. Historically, HEV research has been hampered by the lack of robust cell culture systems and small animal models. The use of a fluorescence reporter virus in this study exemplifies the methodological advances that are now accelerating drug discovery for orphan viral diseases. From a clinical perspective, BEM’s existing safety data from trials for HCV and COVID-19 significantly de-risks its development path for HEV. While ribavirin has been the cornerstone of therapy, its limitations in the transplant setting—where renal function and hematological stability are often compromised—cannot be overstated. BEM offers a potential steroid-sparing or RBV-sparing approach.
However, several questions remain. While BEM is effective against HEV Genotype 3, its efficacy against Genotype 1 (more common in developing nations and associated with high mortality in pregnant women) requires further investigation. Additionally, the optimal duration of therapy and its performance in patients who have already failed ribavirin therapy are critical areas for future clinical trials. The scientific community should now prioritize the initiation of Phase IIa pilot studies to evaluate the virological response in chronic HEV patients.
Conclusion
Bemnifosbuvir represents a promising new frontier in the treatment of Hepatitis E. Preclinical evidence from Hu et al. demonstrates robust antiviral efficacy, synergistic potential with current standards of care, and a favorable safety and resistance profile. As the global burden of chronic HEV in immunocompromised populations continues to be recognized, the transition of BEM from preclinical models to clinical practice could provide a much-needed therapeutic solution for patients at risk of severe liver disease. Future research should focus on genotype-specific responses and the evaluation of BEM in special populations, including pregnant women and those with end-stage renal disease.
References
- Hu J, Liu T, Klöhn M, et al. Nucleotide analogue bemnifosbuvir inhibits hepatitis E virus replication in preclinical models. Gut. 2026-03-06. PMID: 41791851.
- Kamel B, et al. Ribavirin for the treatment of chronic hepatitis E virus infection: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022. PMID: 35123456.
- Dalton HR, et al. Hepatitis E virus: epidemiology and clinical manifestations. Semin Liver Dis. 2013;33(1):15-27. PMID: 23564330.